Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 7/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | NPM1 | P06748 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256522 | 0.92 | KHK (0.39) | TOP2ATOP2BCHEK1NR3C1HDAC8 | |
| SCHEMBL5246548 | 0.90 | CHEK1 (0.44) | TOP2ATOP2BCHEK1ESR1ESR2 | |
| SCHEMBL5252106 | 0.88 | CHEK1 (0.43) | TOP2ATOP2BCHEK1KHKMEN1 | |
| SCHEMBL5252277 | 0.87 | HTR6 (0.43) | CHEK1HDAC8KHKFFAR4NPM1 | |
| SCHEMBL5250845 | 0.86 | KHK (0.37) | TOP2ATOP2BKHKFFAR4NPM1 | |
| SCHEMBL5247487 | 0.84 | ALK (0.52) | NPM1ALK | |
| SCHEMBL5247480 | 0.83 | CHEK1 (0.43) | CHEK1NR3C1HDAC8KHKFFAR4 | |
| SCHEMBL5251727 | 0.82 | CYP11B2 (0.48) | CHEK1HDAC8FGFR1MEN1KMT2A | |
| SCHEMBL5250377 | 0.81 | CHEK1 (0.45) | CHEK1NR3C1HDAC8KHK | |
| SCHEMBL5252304 | 0.80 | CYP1A1 (0.46) | NPM1ALKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614683-B1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMA (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1218348-B1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7141587-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1614683-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS. INC. | 2005-06-09 | — | — | US | disclosed |
| US-6891044-B2 | Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6884890-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | TOP2A 2349/4885TOP2B 1967/4885CHEK1 320/4885 |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | TOP2A 2349/4885TOP2B 1967/4885CHEK1 320/4885 |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | TOP2A 2349/4885TOP2B 1967/4885CHEK1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.